2024
Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDisease
2023
S1006 Comparison of Upadacitinib Induction in Tofacitinib Exposed and Naïve Patients With Inflammatory Bowel Disease: A Real World Multi-Center Study
Almomen H, Alomar I, McMillan C, Gaidos J, Proctor D, AlMutairdi A, Al-Bawardy B. S1006 Comparison of Upadacitinib Induction in Tofacitinib Exposed and Naïve Patients With Inflammatory Bowel Disease: A Real World Multi-Center Study. The American Journal Of Gastroenterology 2023, 118: s761-s762. DOI: 10.14309/01.ajg.0000953664.83573.de.Peer-Reviewed Original ResearchOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2022
Tu1429: FREQUENCY AND CHARACTERISTICS OF NUTRITION ASSESSMENT IN HOSPITALIZED ULCERATIVE COLITIS PATIENTS
Levine L, Sharma S, McMillan C, Li D, Gaidos J, Proctor D, Al Bawardy B. Tu1429: FREQUENCY AND CHARACTERISTICS OF NUTRITION ASSESSMENT IN HOSPITALIZED ULCERATIVE COLITIS PATIENTS. Gastroenterology 2022, 162: s-957. DOI: 10.1016/s0016-5085(22)62267-4.Peer-Reviewed Original Research
2021
THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Gastroenterology 2021, 160: s62. DOI: 10.1053/j.gastro.2021.01.159.Peer-Reviewed Original Research
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritisS0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease
Hussain N, Proctor D, Ruggiero E, Al-Bawardy B. S0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2020, 115: s356-s356. DOI: 10.14309/01.ajg.0000704884.71749.ca.Peer-Reviewed Original Research
2018
THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA
Brandt E, Haghighat L, Garcia-Tsao G, Henderson K, Pollak J, Proctor D, Young L. THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA. Journal Of The American College Of Cardiology 2018, 71: a2393. DOI: 10.1016/s0735-1097(18)32934-6.Peer-Reviewed Case Reports and Technical Notes
2016
Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis
Parian A, Limketkai B, Koh J, Brant SR, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro MD, Rioux JD, Schumm P, Taylor KD, Silverberg MS, Steinhart AH, Hernaez R, Lazarev M. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 2016, 66: 1390. PMID: 27196594, PMCID: PMC5065377, DOI: 10.1136/gutjnl-2016-311550.Peer-Reviewed Original ResearchConceptsUC diagnosisDisease courseImpact of appendectomyRisk of colectomyTiming of appendectomyIndependent risk factorMilder disease courseSeverity of diseaseDevelopment of UCColectomy rateFuture colectomyEarly appendectomyClinical courseMultivariable analysisRisk factorsAppendectomyColectomyLarge cohortHigh riskPatientsDiagnosisConsortium databaseNational InstituteRiskUC
2012
Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset Patients
Ha C, Bayless T, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Brant S. Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset Patients. Gastroenterology 2012, 142: s-253-s-254. DOI: 10.1016/s0016-5085(12)60955-x.Peer-Reviewed Original Research
2010
ChemInform Abstract: Spectrum of Histologic Changes in Colonic Biopsies in Patients Treated with Mycophenolate Mofetil
Selbst M, Ahrens W, Robert M, Friedman A, Proctor D, Jain D. ChemInform Abstract: Spectrum of Histologic Changes in Colonic Biopsies in Patients Treated with Mycophenolate Mofetil. ChemInform 2010, 41: no-no. DOI: 10.1002/chin.201010274.Peer-Reviewed Original Research
2009
Phenotypic and Genotypic Characteristics of Inflammatory Bowel Disease in French Canadians: Comparison With a Large North American Repository
Elkadri A, Bitton A, Cohen A, Griffiths A, Deslandres C, Proctor D, McGovern D, Langelier D, Bernard E, Torres E, Wild G, Nguyen G, Jobin G, Aumais G, Steinhart H, Rioux J, Cho J, Bhat M, Silverberg M, Regueiro M, Goyette P, Pare P, Lahaie R, Duerr R, Brant S, Dassopoulos T. Phenotypic and Genotypic Characteristics of Inflammatory Bowel Disease in French Canadians: Comparison With a Large North American Repository. The American Journal Of Gastroenterology 2009, 104: 2233. PMID: 19513023, PMCID: PMC2742627, DOI: 10.1038/ajg.2009.267.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCrohn's diseaseBowel diseaseUlcerative colitisSingle nucleotide polymorphismsManagement of IBDCaucasian IBD populationsSmall bowel diseaseFrench-Canadian patientsExtraintestinal manifestationsCurrent smokersFormer smokersIBD phenotypeIBD populationCD patientsSmoking statusIncreased prevalenceKidney diseaseSurgical historyCaucasian patientsDisease behaviorFamily historyPatientsAnatomical locationDisease
2005
Enteroscopic Evaluation of the Gastrointestinal Tract in Symptomatic Patients With Hereditary Hemorrhagic Telangiectasia
Proctor DD, Henderson KJ, Dziura JD, Longacre AV, White RI. Enteroscopic Evaluation of the Gastrointestinal Tract in Symptomatic Patients With Hereditary Hemorrhagic Telangiectasia. Journal Of Clinical Gastroenterology 2005, 39: 115-119. PMID: 15681905, DOI: 10.1097/01.mcg.0000150193.15978.f9.Peer-Reviewed Original ResearchConceptsHereditary hemorrhagic telangiectasiaStomach/duodenumHemorrhagic telangiectasiaGastrointestinal bleedingNumber of telangiectasesSymptomatic adult patientsCross-sectional studyAutosomal dominant diseaseDistal stomachSymptomatic patientsAdult patientsMedian numberIndividual patientsGastrointestinal tractPatientsTelangiectasesDuodenumJejunal onesJejunumLarger telangiectasesStomachDominant diseaseBleedingAnemiaTelangiectasia
2003
Critical issues in digestive diseases
Proctor DD. Critical issues in digestive diseases. Clinics In Chest Medicine 2003, 24: 623-632. PMID: 14710694, DOI: 10.1016/s0272-5231(03)00103-5.Peer-Reviewed Original ResearchRole of Interstitial Cells of Cajal in Motility Disorders of the Bowel
Jain D, Moussa K, Tandon M, Culpepper-Morgan J, Proctor DD. Role of Interstitial Cells of Cajal in Motility Disorders of the Bowel. The American Journal Of Gastroenterology 2003, 98: ajg2003146. PMID: 12650797, DOI: 10.1111/j.1572-0241.2003.07295.x.Peer-Reviewed Original ResearchConceptsMechanical bowel obstructionMotility disordersBowel obstructionNormal controlsInterstitial cellsPolyclonal c-kit antibodyAge-matched normal controlsBowel motility disordersNeonatal meconium ileusSpecific histological changesAdministration of drugsIndirect immunoperoxidase methodC-kit antibodyBowel dysmotilityMechanical obstructionSystemic disordersMeconium ileusC-kit receptorHistological changesNeuropathic formPatientsPatchy areasImmunoperoxidase methodMasson's trichromeIntestinal tractDiagnosis and Management of Gastrointestinal Bleeding in Patients With Hereditary Hemorrhagic Telangiectasia
Longacre AV, Gross CP, Proctor D, Henderson KJ, Gallitelli M, White R. Diagnosis and Management of Gastrointestinal Bleeding in Patients With Hereditary Hemorrhagic Telangiectasia. The American Journal Of Gastroenterology 2003, 98: 59. PMID: 12526937, DOI: 10.1111/j.1572-0241.2003.07185.x.Peer-Reviewed Original ResearchConceptsBlood transfusion requirementsHereditary hemorrhagic telangiectasiaTransfusion requirementsGI bleedingMean HbDrug therapyHHT patientsHemorrhagic telangiectasiaEthinyl estradiol/norethindroneHigher blood transfusion requirementsIndividual patient basisLower mean HbGastrointestinal bleedingMean followRed blood cellsConsecutive patientsEndoscopic treatmentSignificant bleedingMean ageClinical evaluationBleedingPatient basisPatientsOptimal managementAminocaproic acid
2000
Absence of c-kit + cells in resected segments of patients with chronic intestinal pseudo-obstruction (CIIP)
Moussa K, Proctor D, Jain D, Culpepper-Morgan J. Absence of c-kit + cells in resected segments of patients with chronic intestinal pseudo-obstruction (CIIP). Gastroenterology 2000, 118: a866. DOI: 10.1016/s0016-5085(00)85606-1.Peer-Reviewed Original Research